Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

Journal of the American Academy of Dermatology - Tập 75 Số 3 - Trang 494-503.e6 - 2016
Amy S. Paller1, Wynnis L. Tom2,3, Mark Lebwohl4, Robin L. Blumenthal5, Mark Boguniewicz6,7, Robert S. Call8, Lawrence F. Eichenfield2,3, Douglass W. Forsha9, William C. Rees10, Eric L. Simpson11, Mary Spellman5, Linda Stein Gold12, Andrea L. Zaenglein13, Matilda H. Hughes5, Lee T. Zane5, Adelaide A. Hebert14
1Northwestern University Feinberg School of Medicine, Chicago, Illinois
2Rady Children's Hospital-San Diego, San Diego, California
3University of California, San Diego, La Jolla, California
4Icahn School of Medicine at Mount Sinai, New York, New York
5Anacor Pharmaceuticals Inc, Palo Alto, California
6National Jewish Health, Denver, Colorado
7University of Colorado School of Medicine, Denver, Colorado
8Clinical Research Partners, Richmond, Virginia
9Jordan Valley Dermatology and Research Center, West Jordan, Utah
10Pi-Coor Clinical Research, Burke, Virginia
11Oregon Health and Science University, Portland, Oregon
12Henry Ford Health System, Detroit, Michigan
13Pennsylvania State University, Hershey, Pennsylvania
14University of Texas Health Science Center Houston, Houston, Texas

Tóm tắt

Từ khóa


Tài liệu tham khảo

Bieber, 2010, Atopic dermatitis, Ann Dermatol, 22, 125, 10.5021/ad.2010.22.2.125

Bieber, 2008, Atopic dermatitis, N Engl J Med, 358, 1483, 10.1056/NEJMra074081

Eichenfield, 2014, Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies, J Am Acad Dermatol, 71, 116, 10.1016/j.jaad.2014.03.023

Odhiambo, 2009, Global variations in prevalence of eczema symptoms in children from ISAAC phase three, J Allergy Clin Immunol, 124, 1251, 10.1016/j.jaci.2009.10.009

Arkwright, 2013, Management of difficult-to-treat atopic dermatitis, Journal of Allergy Clin Immunol Pract, 1, 142, 10.1016/j.jaip.2012.09.002

Blume-Peytavi, 2012, Atopic dermatitis in children: management of pruritus, J Eur Acad Dermatol Venereol, 26, 2, 10.1111/j.1468-3083.2012.04710.x

Mollanazar, 2015, Mediators of chronic pruritus in atopic dermatitis: getting the itch out?, Clin Rev Allergy Immunol

Schneider, 2013, Atopic dermatitis: a practice parameter update 2012, J Allergy Clin Immunol, 131, 295, 10.1016/j.jaci.2012.12.672

Ellis, 2002, Cost of atopic dermatitis and eczema in the United States, J Am Acad Dermatol, 46, 361, 10.1067/mjd.2002.120528

Margolis, 2014, Persistence of mild to moderate atopic dermatitis, JAMA Dermatol, 150, 593, 10.1001/jamadermatol.2013.10271

Carr, 2013, Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations, Paediatr Drugs, 15, 303, 10.1007/s40272-013-0013-9

Siegfried, 2013, Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice, Am J Clin Dermatol, 14, 163, 10.1007/s40257-013-0020-1

Walling, 2010, Update on the management of chronic eczema: new approaches and emerging treatment options, Clin Cosmet Investig Dermatol, 3, 99, 10.2147/CCID.S6496

Jimenez, 2001, Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation, J Pharmacol Exp Ther, 299, 753

Baumer, 2007, Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis, Inflamm Allergy Drug Targets, 6, 17, 10.2174/187152807780077318

Grewe, 1982, Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness, J Allergy Clin Immunol, 70, 452, 10.1016/0091-6749(82)90008-2

Heskel, 1984, Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents, J Am Acad Dermatol, 11, 422, 10.1016/S0190-9622(84)70184-8

Butler, 1983, Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis, J Allergy Clin Immunol, 71, 490, 10.1016/0091-6749(83)90467-0

Hanifin, 1990, Phosphodiesterase and immune dysfunction in atopic dermatitis, J Dermatol Sci, 1, 1, 10.1016/0923-1811(90)90003-V

Hanifin, 1996, Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis, J Invest Dermatol, 107, 51, 10.1111/1523-1747.ep12297888

Moustafa, 2014, A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology, Dermatol Online J, 20, 22608, 10.5070/D3205022608

Wittmann, 2013, Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases, Dermatol Ther (Heidelb), 3, 1, 10.1007/s13555-013-0023-0

Jarnagin, 2016, Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis, J Drugs Dermatol, 15, 390

Akama, 2009, Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis, Bioorg Med Chem Lett, 19, 2129, 10.1016/j.bmcl.2009.03.007

Dastidar, 2007, Therapeutic benefit of PDE4 inhibitors in inflammatory diseases, Curr Opin Investig Drugs, 8, 364

Freund, 2012, Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center, FEBS Lett, 586, 3410, 10.1016/j.febslet.2012.07.058

Nazarian, 2009, AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis, Curr Opin Investig Drugs, 10, 1236

Jimenez, 2004, Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes, Cell Signal, 16, 1363, 10.1016/j.cellsig.2004.04.002

Zane, 2016, Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies, Future Med, 8, 853

Zane, 2016, AN2728 Topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study, Pediatr Dermatol, 10.1111/pde.12872

Murrell, 2015, Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2A, vehicle-controlled, proof-of-concept study, J Drugs Dermatol, 14, 1108

Stein Gold, 2015, A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis, J Drugs Dermatol, 14, 1394

Tom, 2016, Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study, Pediatr Dermatol, 33, 150, 10.1111/pde.12780

Hanifin, 1980, Diagnostic features of atopic dermatitis, Acta Dermatol Venereol, 92, 44, 10.2340/00015555924447

Garcia, 2012, Frontiers of rapid itch relief: a review of methylprednisolone aceponate, J Eur Acad Dermatol Venereol, 26, 9

Schachner, 2005, Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study, Pediatrics, 116, e334, 10.1542/peds.2004-2638

Callen, 2007, A systematic review of the safety of topical therapies for atopic dermatitis, Br J Dermatol, 156, 203, 10.1111/j.1365-2133.2006.07538.x

2000

2001

Berth-Jones, 2003, Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study, BMJ, 326, 1367, 10.1136/bmj.326.7403.1367

Sobell, 2016, Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis, Acta Derm Venereol, 96, 514, 10.2340/00015555-2360

Stull, 2015, Advances in therapeutic strategies for the treatment of pruritus, Expert Opin Pharmacother, 1-17, 671

Andoh, 2014, Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis, Exp Dermatol, 23, 359, 10.1111/exd.12377

Wakita, 2015, A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fiber nerves, Exp Dermatol, 24, 215, 10.1111/exd.12606

Yosipovitch, 2008, What causes itch in atopic dermatitis?, Curr Allergy Asthma Rep, 8, 306, 10.1007/s11882-008-0049-z